METASTATIC NON-SMALL CELL LUNG CANCER

This study is testing whether combining an approved immunotherapy drug (tislelizumab) with new experimental drugs, with or without standard chemotherapy, can better control advanced non-small cell lung cancer. It will enroll 400 patients who have not yet received treatment for th…

This study is testing if a simple blood test, taken at different times, can help doctors see how well a patient's advanced lung cancer is responding to an immunotherapy drug called pembrolizumab. Based on the blood test results, doctors will decide if the patient should continue …

This large, late-stage study is testing whether adding an investigational drug called ramucirumab to a standard targeted therapy (erlotinib) works better for people newly diagnosed with a specific type of advanced lung cancer. It involves 545 participants whose cancer has spread …

This large, late-stage study is comparing two different drug combinations for people with advanced non-small cell lung cancer that has spread. About 1200 participants will receive either a new drug called volrustomig plus standard chemotherapy, or an existing drug called pembroli…

This trial is testing a new three-drug combination for people with advanced non-small cell lung cancer that has spread and stopped responding to standard immunotherapy. The study aims to see if adding two drugs (dupilumab and anakinra) to a common immunotherapy can make it work a…

This study is testing if adding a new drug called relatlimab to a standard treatment (nivolumab plus chemotherapy) works better for people with advanced or recurrent non-small cell lung cancer. It will involve about 468 adults who have not yet received treatment for their advance…

This large study is testing whether adding a new targeted drug (datopotamab deruxtecan) to standard immunotherapy helps people with advanced non-small cell lung cancer live longer without their cancer getting worse. It will compare this new combination to the current standard tre…

This trial aimed to test a new cell therapy for metastatic non-small cell lung cancer. It planned to use a patient's own tumor-fighting immune cells, genetically edited with CRISPR technology to remove a molecular 'brake' called CISH. The goal was to see if these supercharged cel…

This early-stage study is testing an experimental drug called furmonertinib for people with advanced lung cancer that has specific genetic mutations. The trial aims to find the safest and most effective dose while checking if the drug can shrink tumors. It involves 160 patients w…

This study is testing if a new under-the-skin injection of a cancer drug works as well as the standard intravenous (IV) drip. It involves adults with advanced non-small cell lung cancer who are receiving their first treatment. The main goal is to see if the body processes the inj…

This study is testing whether adding an experimental cancer vaccine called Tedopi to standard second-line drugs (docetaxel or nivolumab) can help control metastatic lung cancer that has progressed after initial treatment. It will involve about 105 patients who have a specific gen…

This study is testing if a new under-the-skin injection of the cancer drug pembrolizumab works as well and is as safe as the standard intravenous (IV) infusion. It is for Japanese adults with advanced non-small cell lung cancer who are receiving it along with chemotherapy as thei…

This study is testing if adding an investigational drug called APL-101 to the standard first-line treatment (osimertinib) can help control advanced lung cancer for a longer period. It is for adults whose cancer has a specific genetic change (EGFR mutation) and has not worsened af…